Abstract

This case deals with the planned market expansion of Metagenom Bio Inc. (MBI), a Canadian microbiome company that specializes in designing and structuring novel environmental monitoring and remediation technology and processes. The case revolves around the situation in 2019 facing Patrick Ang, the CEO of MBI, who has to take strategic decisions at a crucial point of MBI’s development of a potential entry to China while keeping confidential the details of the IP of MBI.

Learning Objectives

 To provide students with a basic understanding of the business environment in China and to analyze the opportunities and challenges present to a foreign business entity. Students should be encouraged to analyze critically the viability of whether it is possible for a business entity such as MBI to keep its IP confidential while at the same time expanding its commercial operations into other jurisdictions.